Little is known regarding the early aspects of ovarian carcinogenesis. As a consequence,
the identification of women at risk for the disease is based primarily on clinical grounds, with …

Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases
projected in the United States for 2006. Two different clinicopathologic subtypes are …

Progesterone is a key hormone in the endometrium that opposes estrogen-driven growth.
Insufficient progesterone will result in unopposed estrogen action that could lead to the …

Introduction Progestogens are widely used for the conservative treatment of endometrial
hyperplasia and early endometrial cancer. Nevertheless, they do not achieve the regression …

More than 15 case–control studies and at least four large cohort studies demonstrated a
decrease in the risk of endometrial cancer of about 50% for ever use of combined oral …

Introduction Progestins are used as conservative treatment of endometrial hyperplasia (EH)
and early endometrial cancer (EEC). We aimed to assess whether immunohistochemical …

OBJECTIVES:: The effect on progesterone and estrogen receptor expression in glands and
stroma after two different treatment regimens of endometrial hyperplasia was determined …

Introduction Endometrial hyperplasia has a high risk for malignant transformation and
relapses; existing mini-invasive treatments may lead to irrevocable endometrium …

This ninety-first volume of IARC Monographscontains evaluations of the carcinogenic
hazard to humans of combined estrogen-progestogen contraceptives and combined …

Background The effectiveness of conservative treatment of endometrial carcinoma (EC) with
oral progesterone therapy, such as medroxyprogesterone acetate (MPA), can be blunted …